Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2- fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-α]pyrazine-4-spiro-3'- pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners

Journal of Medicinal Chemistry

Volumn 41, Issue 21, 1998, Pages 4118-4129

  Negoro, Toshiyuki ^a   Murata, Makoto ^a   Ueda, Shozo ^a   Fujitani, Buichi ^a   Ono, Yoshiyuki ^a   Kuromiya, Akelmi ^a   Komiya, Masanobu ^a   Suzuki, Kenji ^a   Matsumoto, Jun Ichi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BROMO 2 FLUOROBENZYL) 1,2,3,4 TETRAHYDROPYRROLO[1,2 A]PYRAZINE 4 SPIRO 3' PYRROLIDINE 1,2',3,5' TETRONE; ALDOSE REDUCTASE INHIBITOR; PONALRESTAT; PYRAZINE DERIVATIVE; RANIRESTAT; SX 3030; SX 3202; TETRAHYDROPYRROLO[1,2 A]PYRAZINE DERIVATIVE; TOLRESTAT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALDEHYDE REDUCTASE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; LENS, CRYSTALLINE; MALE; MOLECULAR CONFORMATION; PYRAZINES; RATS; RATS, WISTAR; SCIATIC NERVE; SORBITOL; SPIRO COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 0032497704     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9802968     Document Type: Article

References (33)

1. (a) Kador, P. F.; Kinoshita, J. H.; Sharpless, N. E. Aldose Reductase Inhibitors: A Potential New Class of Agents for the Pharmacological Control of Certain Diabetic Complications. J. Med. Chem. 1985, 28, 841-849.
2. (b) Lee, Y. S.; Pearlstein, R.; Kador, P. F. Molecular Modeling Studies of Aldose Reductase Inhibitors. J. Med. Chem. 1994, 37, 787-792.
3. (a) Sestanj, K.; Bellini, F.; Fung, S.; Abraham, N.; Treasurywala, A.; Humber, L.; Simard-Duquesne, N.; Dvornik, D. N-[[5-(Trifluoromethyl)-6-methoxy-l-naphthalenyl]thioxomethyl]-N-methylglycine (Tolrestat), a Potent, Orally Active Aldose Reductase Inhibitor. J. Med. Chem. 1984, 27, 255-256.
4. (b) Wrobel, J.; Millen, J.; Sredy, J.; Dietrich, A.; Gorham, B. J.; Malamas, M.; Kelly, J. M.; Bauman, J. G.; Harrison, M. C.; Jones, L. R.; Guinosso, C.; Sestanj, K. Syntheses of Tolrestat Analogues Containing Additional Substituents in the Ring and Their Evaluation as Aldose Reductase Inhibitors. Identification of Potent, Orally Active 2-Fluoro Derivatives. J. Med. Chem. 1991, 34, 2504-2520.
5. (c) Simard-Duquesne, N.; Greselin, E.; Dubuc, J.; Dvornik, D. The Effects of a New Aldose Reductase Inhibitor (Tolrestat) in Galactosemic and Diabetic Rats. Metabolism 1985, 34, 885-892.
6. (d) Malamas, M. S.; Sestanj, K.; Millen, J. Synthesis and biological evaluation of tolrestat metabolites. Eur. J. Med. Chem. 1991, 26, 197-200.
7. (a) Kikkawa, R.; Hatanaka, I.; Yasuda, H.; Kobayashi, N.; Shigeta, Y.; Terashima, H.; Morimura, T.; Tsuboshima, M. Effects of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenilidene]rhodanine (NO2235), on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetlogia 1983, 24, 290-292.
8. (b) Terashima, H.; Hama, K.; Yamamoto, R.; Tsuboshima, M.; Kikkawa, R.; Hatanaka, I.; Shigeta, Y. Effects of a New Aldose Reductase Inhibitor on Various Tissues in Vitro. J. Pharmacol. Exp. Ther. 1984, 229, 226-230.
9. (c) Ishida, T.; In, Y.; Inoue, M.; Tanaka, C. Conformation of (Z)-3-Carboxymethyl-[(2E)-2-methyl-3-phenylpropenylidene]rhodanine (Epalrestat), a Potent Aldose Reductase Inhibitor: X-ray Crystallographic, Energy Calculational, and Nuclear Magnetic Resonance Studies. J. Chem. Soc., Perkin Trans. 2 1990, 1085-1091.
10. Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zenbrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, Potent Aldose Reductase Inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1- phthalazineacetic Acid (Zopolrestat) and Congeners. J. Med. Chem. 1991, 34, 108-122.
11. (a) Mizuno, K.; Kato, N.; Matsubara, A.; Nakano, K.; Kurono, M. Effect of a New Aldose Reductase Inhibitor, (2S,4S)-6-Fluoro-2′,5′-Dioxospiro[Chroman-4,4′-Imidazolidine]- 2-Carboxamide (SNK-860), on the Slowing of Motor Nerve Conduction Velocity and Metabolic Abnormalities in the Peripheral Nerve in Acute Streptozotocin-Induced Diabetic Rats. Metabolism 1992, 41, 1081-1086.
12. (b) Yamaguchi, T.; Miura, K.; Usui, T.; Unno, R.; Matsumoto, Y.; Fukushima, M.; Mizuno, K.; Kondo, Y.; Baba, Y.; Kurono, M. Synthesis and Aldose Reductase Inhibitory Activity of 2-Substituted-6-Fluoro-2,3-dihydrospiro[4H-1-benzopyran-4,4′- imidazolidine]-2′,5′-diones. Arzneim. -Forsch. /Drug Res. 1994, 44 (1), 344-348.
13. (a) Ao, S.; Shingu, Y.; Kikuchi, C.; Takano, Y.; Nomura, K.; Fujiwara, T.; Ohkubo, Y.; Notsu, Y.; Yamaguchi, I. Characterization of a novel aldose reductase inhibitor FR-74366, and its effects on diabetic cataract and neuropathy in the rats. Metabolism 1991, 40, 77-87.
14. (b) Tanaka, Y.; Kadoh, Y.; Ishikawa, H. Effects of hypophysectomy and testosterone treatment on the urinary excretion of zenarestat in rats. Xenobiotica 1992, 22, 51-55.
15. (c) Tanaka, Y.; Sekiguchi, M.; Sawamoto, T.; Katami, Y.; Ueda, T.; Esumi, Y.; Noda, K. Absorption, distribution and excretion of zenarestat, a new aldose reductase inhibitor, in rats and dogs. Xenobiotica 1992, 22, 57-64.
16. (d) Tanaka, Y.; Fujiwara, T.; Esumi, Y. Sex difference in the excretion of zenarestat in mice, rats, dogs and humans. Xenobiotica 1992, 22, 941-947.
17. Malamas, M. S.; Hohman, T. C.; Millen, J. Novel Spirosuccinimide Aldose Reductase Inhibitors Derived from Isoquinoline1,3-diones: 2-[(4-Bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinolme-4(1H),3′- pyrrolidine]-1,2′,3,5′(2H)-tetrone and Congeners 1. J. Med. Chem. 1994, 37, 2043-2058.
18. Ishii, A.; Kotani, T.; Nagaki, Y.; Shibayama, Y.; Toyomaki, Y.; Okukado, N.; Ienaga, K.; Okamoto, K. Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine1-acetic Acids. J. Med. Chem. 1996, 39, 1924-1927.
19. (a) Brittain, D. R.; Wood, R. (ICI, Ltd.) EP 2,895, 1979.
20. (b) Stribling, D.; Mirrlees, D. J.; Harrisoh, H. E.; Earl, D. C. N. Properties of ICI 128,436, a Novel Aldose Reductase Inhibitor, and Its Effects on Diabetic Complications in the Rat. Metabolism 1985, 34, 336-344.
21. (c) Poulsom, R. Inhibition of Hexonate Dehydrogenase and Aldose Reductase From Bovine Retina By Sorbinil, Statil, M79175 and Valproate. Biochem. Pharmacol. 1986, 35, 2955-2959.
22. (d) Ward, W. H. J.; Sennitt, C. M.; Ross, H.; Dingle, A.; Timms, D.; Mirrlees, D. J.; Tuffin, D. P. Ponalrestat; A Potent and Specific Inhibitor of Aldose Reductase. Biochem. Pharmcol. 1990, 39, 337-346.
23. (a) Nudelman, A.; Karoly, H.; Braun, F.; Böhme, E. H. W.; Erickson, R. C. Semisynthetic Cephalosporins. Synthesis and Structure-Activity Relationships of 7-(1-Pyrryl)- and 7-(1-IndolyDacetamidocephalosporin Derivatives. J. Med. Chem. 1978, 21, 962-964.
24. (b) Josey, A. D.; Jenner, E. L. N-Functionally Substituted Pyrroles. J. Chem. Soc. 1962, 27, 2466-2470.
25. Bailey, D. M.; Johnson, R. E.; Albertson, N. F. Ethyl Pyrrole-2-Carboxylate. Org. Synth. 1971, 51, 100-102.
26. Bélanger, P. Electrophilic Substitutions on 2-Trichloropyrrole. Tetrahedron Lett. 1979, 27, 2505-2508.
27. Murakami, Y.; Tani, M.; Ariyasu, T.; Nishiyama, C.; Watanabe, T.; Yokoyama, Y. The Friedel-Crafts Acylation of Ethyl Pyrrole-2-Carboxylate. Scope, Limitations, and Application to Synthesis of 7-Substituted Indoles. Heterocycles 1988, 27, 1855-1860.
28. Warren, C. B.; Minard, R. D.; Matthews, C. N. Synthesis of α-Cyanoglycine N-Carboxyanhydride and α-Cyanoglycine. J. Org. Chem. 1974, 39, 3375-3378.
29. Kabalka, G. W.; Deshpande, S. M.; Wadgaonkar, P. P.; Chatla, N. The Transformation of Nitriles into Amides Using Sodium Percarbonate. Synth. Commun. 1990, 20, 1445-1451.
30. Hayman, S.; Kinoshita, J. H. Isolation and Properties of Lens Aldose Reductase. J. Biol. Chem. 1965, 240, 877-882.
31. Clements, R. S.; Morrison, A. D., Jr.; Winegrad, A. I. Polyol Pathway in Aorta: Regulation by Hormones. Science 1969, 166, 1007-1008.
32. (a) Sarges, R.; Schnur, R. C.; Belletire, J. L.; Peterson, M. J. Spiro Hydantoin Aldose Reductase Inhibitors. J. Med. Chem. 1988, 31, 230-243.
33. (b) Sarges, R.; Goldstein, S. W.; Welch, W. M.; Swindell, A. C.; Siegel, T. W.; Beyer, T. A. Spiro Hydantoin Aldose Reductase Inhibitors Derived from 8-Aza-4-chromanones. J. Med. Chem. 1990, 33, 1859-1865.